NASDAQ$MDXG
Mimedx Group Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported net sales of $67.4 million and net income of $2.2 million.
MiMedx Group, Inc. reported Q4 2021 net sales of $67.4 million and a net income of $2.2 million. The company's Advanced Wound Care products saw a 13% increase in sales, driven by growth in the AMNIOFIX® sheet portfolio and the EPICORD® Expandable product line. Looking ahead, MiMedx is well-poised for continued growth, with plans for the EPIFIX launch in Japan and new product innovations in the U.S.
- Fourth quarter net sales reached $67.4 million.
- Net income for the fourth quarter was $2.2 million.
- Advanced Wound Care products experienced a 13% sales increase.
- The company is preparing for the EPIFIX launch in Japan and new product innovations in the U.S.
Headline financials
Revenue & EPS history
Mimedx · Revenue · Quarterly
$67.4M
Forward guidance
The Company expects net sales of its continuing portfolio of products to grow 11% to 14% in 2022; we expect mid-single digit growth in the first quarter, building to a high-teens or 20% growth in the fourth quarter. The Company expects gross margin for 2022 to be slightly lower than 2021. Management anticipates beginning the Phase 3 KOA clinical trial program in 2022, and expects the cost to be approximately $30 million, representing $15 million per trial for two trials incurred over the next three years. The Company expects research and development expenses to increase over 2021 as it plans and begins these new clinical trials and executes other product development initiatives.
Tailwinds
- Net sales of its continuing portfolio of products are expected to grow 11% to 14% in 2022
- Mid-single digit growth is expected in the first quarter of 2022.
- High-teens or 20% growth is expected in the fourth quarter of 2022.
- Phase 3 KOA clinical trial program is anticipated to begin in 2022.
- Gross margin for 2022 is expected to be slightly lower than 2021.
Headwinds
- Clinical trials may face delays or alterations.
- Access to hospitals and healthcare provider facilities could be restricted due to the COVID-19 pandemic or other factors.
- The results of scientific research are uncertain and may have little or no value.
- The effectiveness of amniotic tissue as a therapy for particular indications or conditions is the subject of further scientific and clinical studies.
- The company may alter the timing and amount of planned expenditures for research and development based on the results of clinical trials and other regulatory developments.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+1.7%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+7.2%
Avg return
30 days after
53%
34 / 64 earnings
Positive
+37.9%
Q1 2023
Best reaction
-23.3%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -9.1% | +6.2% | +8.2% | |
| Q4 2025 | -0.9% | -8.8% | -28.8% | |
| Q3 2025 | +2.6% | +7.0% | -4.3% | |
| Q1 2025 | -8.1% | -3.9% | -6.5% | |
| Q4 2024 | +1.6% | +1.1% | -5.9% | |
| Q3 2024 | +17.9% | +22.7% | +59.2% | |
| Q2 2024 | -12.0% | -17.7% | -9.9% | |
| Q1 2024 | +16.8% | +17.7% | +13.7% | |
| Q4 2023 | -2.9% | -1.7% | -8.3% | |
| Q3 2023 | +6.7% | +10.9% | +26.5% | |
| Q2 2023 | -4.6% | -4.2% | -8.1% | |
| Q1 2023 | +37.9% | +49.1% | +50.4% | |
| Q4 2022 | -11.4% | -6.4% | -29.0% | |
| Q3 2022 | -3.6% | +1.3% | +12.6% | |
| Q2 2022 | +8.2% | +15.5% | +2.3% | |
| Q1 2022 | +11.1% | -8.9% | -4.8% | |
| Q4 2021 | +1.4% | -1.6% | -4.0% | |
| Q3 2021 | +18.8% | +22.6% | +2.5% | |
| Q2 2021 | -2.5% | +1.4% | +23.4% | |
| Q1 2021 | -2.9% | -5.0% | +2.0% | |
| Q4 2020 | -15.3% | -13.4% | +13.8% | |
| Q3 2020 | +3.4% | -8.2% | -5.6% | |
| Q2 2020 | +2.3% | +4.2% | +14.4% | |
| Q2 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2020 | +8.2% | +3.2% | +18.2% | |
| Q4 2018 | +8.2% | +3.2% | +18.2% | |
| Q4 2019 | +8.2% | +3.2% | +18.2% | |
| Q2 2019 | +8.2% | +3.2% | +18.2% | |
| Q1 2018 | +8.2% | +3.2% | +18.2% | |
| Q1 2019 | +8.2% | +3.2% | +18.2% | |
| Q3 2019 | +8.2% | +3.2% | +18.2% | |
| Q4 2017 | -21.6% | -22.1% | -14.0% | |
| Q3 2018 | -1.3% | -8.6% | -7.0% | |
| Q3 2017 | +4.1% | +8.7% | -4.9% | |
| Q2 2017 | +0.7% | +2.1% | +5.9% | |
| Q1 2017 | +8.2% | +19.1% | +17.5% | |
| Q4 2016 | -3.9% | +3.4% | +9.8% | |
| Q3 2016 | +4.9% | +8.0% | +19.1% | |
| Q2 2016 | -0.9% | -1.7% | -5.6% | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -23.3% | — | — | |
| Q2 2015 | -13.5% | — | — | |
| Q1 2015 | +0.9% | — | — | |
| Q4 2014 | +8.7% | — | — | |
| Q3 2014 | +13.2% | — | — | |
| Q2 2014 | +5.5% | — | — | |
| Q1 2014 | -3.8% | — | — | |
| Q4 2013 | +2.2% | — | — | |
| Q3 2013 | -3.5% | — | — | |
| Q2 2013 | +0.8% | — | — | |
| Q1 2013 | -2.2% | — | — | |
| Q4 2012 | +8.5% | — | — | |
| Q3 2012 | +13.5% | — | — | |
| Q2 2012 | -4.8% | — | — | |
| Q1 2012 | +0.0% | — | — | |
| Q4 2011 | +0.0% | — | — | |
| Q3 2011 | -4.2% | — | — | |
| Q2 2011 | -2.5% | — | — | |
| Q1 2011 | -3.7% | — | — | |
| Q4 2010 | +5.8% | — | — | |
| Q3 2010 | +0.0% | — | — | |
| Q2 2010 | -4.8% | — | — | |
| Q1 2010 | +4.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro